CCCC
Q4 2026 EPS Estimate
$-0.21
Nov 5, 2026 · Reports before open
Revenue Estimate
$5M
FY2029E EPS$0.73
FY2030E EPS$5.33

Analyst Sentiment

Wall St. Consensus
Buy
14 analysts·Moderate coverage
66
Score
10 Buy (71%)3 Hold (21%)1 Sell (8%)
Rating Breakdown
Strong Buy
00%
Buy
1071%
Hold
321%
Sell
17%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear
$7.00
+66.7%
Consensus
$7.00
+66.7%
Bull
$7.00
+66.7%
12-Month Target Range14 analysts
$7.00$7.00$7.00
Current $4.20Consensus
Current Price
$4.20
Upside to Consensus
$2.80

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)
FY2027
Rev-3.51%
EPS
FY2028
Rev-13.33%
EPS
FY2029
Rev+4249.65%
EPS
Raw consensus estimates (low / average / high) from covering analysts.
Annual
MetricFY2026EFY2027EFY2028EFY2029EFY2030E
Revenue Avg$21M$21M$18M$778M$2.62B
Low$17M$16M$18M$604M$2.03B
High$27M$26M$18M$967M$3.25B
EBITDA Avg$-21M$-21M$-18M$-778M$-2.62B
Low$-27M$-26M$-18M$-967M$-3.25B
High$-17M$-16M$-18M$-604M$-2.03B
EBIT Avg$-21M$-21M$-18M$-778M$-2.62B
Low$-27M$-26M$-18M$-967M$-3.25B
High$-17M$-16M$-18M$-604M$-2.03B
Net Income Avg$-71M$-76M$-110M$61M$442M
Low$-75M$-83M$-145M$43M$314M
High$-67M$-70M$-75M$80M$582M
EPS Avg$-0.86$-0.92$-1.24$0.73$5.33
Low$-0.91$-1.00$-1.75$0.52$3.79
High$-0.81$-0.84$-0.91$0.97$7.02
Analysts (Rev / EPS)3 / 43 / 45 / 52 / 12 / 1
Quarterly
MetricQ3 2026Q4 2026Q1 2027Q2 2027Q3 2027Q4 2027
Revenue Avg$5M$4M$5M$5M$5M$5M
Low$5M$4M$5M$5M$5M$5M
High$5M$4M$5M$5M$5M$5M
EBITDA Avg$-5M$-4M$-5M$-5M$-5M$-5M
Low$-5M$-4M$-5M$-5M$-5M$-5M
High$-5M$-4M$-5M$-5M$-5M$-5M
EBIT Avg$-5M$-4M$-5M$-5M$-5M$-5M
Low$-5M$-4M$-5M$-5M$-5M$-5M
High$-5M$-4M$-5M$-5M$-5M$-5M
Net Income Avg$-29M$-34M$-35M$-30M$-35M$-36M
Low$-30M$-39M$-35M$-30M$-35M$-36M
High$-27M$-28M$-35M$-30M$-35M$-36M
EPS Avg$-0.22$-0.26$-0.27$-0.23$-0.27$-0.27
Low$-0.23$-0.30$-0.27$-0.23$-0.27$-0.27
High$-0.21$-0.22$-0.27$-0.23$-0.27$-0.27
Analysts (Rev / EPS)2 / 13 / 31 / 11 / 11 / 11 / 1

Earnings Surprises

Recent Analyst Actions

Feb 26, 2026Barclays
C4 Therapeutics (CCCC) PT Raised to $7 at Barclays
Target:$7.00
+149.6%from $2.81
Dec 17, 2025Barclays
C4 Therapeutics price target lowered to $5 from $10 at Barclays
Target:$5.00
+121.2%from $2.26
Sep 23, 2025Wells Fargo
C4 Therapeutics price target raised to $10 from $5 at Wells Fargo
Target:$10.00
+257.1%from $2.80
Sep 22, 2025Barclays
C4 Therapeutics price target raised to $10 from $8 at Barclays
Target:$10.00
+216.5%from $3.16
Sep 16, 2025Barclays
C4 Therapeutics initiated with an Overweight at Barclays
Target:$8.00
+134.6%from $3.41
Sep 15, 2025Stephens
C4 Therapeutics upgraded to Overweight from Equal Weight at Stephens
Target:$6.00
+68.1%from $3.57
Dec 19, 2024Wells Fargo
C4 Therapeutics upgraded to Overweight from Equal Weight at Wells Fargo
Target:$12.00
+178.4%from $4.31
Sep 19, 2024BMO Capital
BMO Capital Reiterates Outperform Rating on C4 Therapeutics (CCCC)
Target:$20.00
+191.1%from $6.87
Jan 3, 2023Wells Fargo
Wells Fargo Maintains Equal-Weight on C4 Therapeutics, Lowers Price Target to $9
Target:$9.00
+42.6%from $6.31
Apr 28, 2022Credit Suisse
Credit Suisse Initiates Coverage On C4 Therapeutics with Underperform Rating, Announces Price Target of $10
Target:$10.00
+13.0%from $8.85
Apr 11, 2022Bank of America Securities
C4 Therapeutics (CCCC) Stock: $15 Price Target From BofA
Target:$15.00
+87.3%from $8.01
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.